Management and outcomes of giant prolactinoma: A series of 71 patients

Oksana Hamidi, Jamie Van Gompel, Lucinda Gruber, Nana Esi Kittah, Diane Donegan, Kenneth A. Philbrick, Kelly K. Koeller, Dana Erickson, Neena Natt, Todd B. Nippoldt, William F. Young, Irina Bancos

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To describe outcomes of patients with giant prolactinoma (≥4 cm) and identify predictors of therapeutic response. Methods: In this retrospective study, complete biochemical and structural response were defined as prolactin (PRL) ≤25 ng/mL and no visible tumor at follow-up, respectively. Results: Giant prolactinoma (median size, 4.8 cm [range, 4 to 9.8 cm]; median PRL, 5,927 ng/mL [range, 120 to 100,000 ng/mL]) was diagnosed in 71 patients. Treatments included: Dopamine agonists (DAs) (n = 70, 99%), surgery (n = 30, 42%), radiation (n = 10, 14%), and somatostatin analogs (n = 2, 3%). Patients treated with DA monotherapy were older compared with those who received subsequent therapies (47 years vs. 28 years; P = .003) but had similar initial PRL and tumor size. Surgically managed patients were younger compared with the nonsurgical group (35 years vs. 46 years; P = .02) and had lower initial PRL (3,121 ng/mL vs. 6,920 ng/mL; P = .02), yet they had similar tumor response. Hypopituitarism was more common following surgery compared to medical management: Adrenal insufficiency (69% vs. 27%; P<.001), hypothyroidism (67% vs. 38%; P = .02), growth hormone deficiency (24% vs. 6%; P = .04), and diabetes insipidus (17% vs. 3%; P = .04). Therapeutic response did not correlate with sex, age, initial PRL, tumor size, or first-line therapy mode. At median follow-up of 4.8 years, the median PRL was 18.3 ng/mL (range, 0.6 to 12,680 ng/mL), and final volume was 0.9 cm3 (range, 0 to 43.0 cm3). In those with available data, 36/65 (55%) patients achieved PRL normalization, and 16/61 (26%) had no visible tumor at follow-up. Conclusion: Most patients with giant prolactinoma have excellent response to DA. Sex, age, initial PRL, and tumor size do not predict therapeutic response.

Original languageEnglish (US)
Pages (from-to)340-352
Number of pages13
JournalEndocrine Practice
Volume25
Issue number4
DOIs
StatePublished - Apr 2019

Fingerprint

Prolactinoma
Prolactin
Dopamine Agonists
Neoplasms
Therapeutics
Adrenal Insufficiency
Hypopituitarism
Diabetes Insipidus
Hypothyroidism
Somatostatin
Growth Hormone
Retrospective Studies
Radiation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Hamidi, O., Van Gompel, J., Gruber, L., Kittah, N. E., Donegan, D., Philbrick, K. A., ... Bancos, I. (2019). Management and outcomes of giant prolactinoma: A series of 71 patients. Endocrine Practice, 25(4), 340-352. https://doi.org/10.4158/EP-2018-0392

Management and outcomes of giant prolactinoma : A series of 71 patients. / Hamidi, Oksana; Van Gompel, Jamie; Gruber, Lucinda; Kittah, Nana Esi; Donegan, Diane; Philbrick, Kenneth A.; Koeller, Kelly K.; Erickson, Dana; Natt, Neena; Nippoldt, Todd B.; Young, William F.; Bancos, Irina.

In: Endocrine Practice, Vol. 25, No. 4, 04.2019, p. 340-352.

Research output: Contribution to journalArticle

Hamidi, O, Van Gompel, J, Gruber, L, Kittah, NE, Donegan, D, Philbrick, KA, Koeller, KK, Erickson, D, Natt, N, Nippoldt, TB, Young, WF & Bancos, I 2019, 'Management and outcomes of giant prolactinoma: A series of 71 patients', Endocrine Practice, vol. 25, no. 4, pp. 340-352. https://doi.org/10.4158/EP-2018-0392
Hamidi O, Van Gompel J, Gruber L, Kittah NE, Donegan D, Philbrick KA et al. Management and outcomes of giant prolactinoma: A series of 71 patients. Endocrine Practice. 2019 Apr;25(4):340-352. https://doi.org/10.4158/EP-2018-0392
Hamidi, Oksana ; Van Gompel, Jamie ; Gruber, Lucinda ; Kittah, Nana Esi ; Donegan, Diane ; Philbrick, Kenneth A. ; Koeller, Kelly K. ; Erickson, Dana ; Natt, Neena ; Nippoldt, Todd B. ; Young, William F. ; Bancos, Irina. / Management and outcomes of giant prolactinoma : A series of 71 patients. In: Endocrine Practice. 2019 ; Vol. 25, No. 4. pp. 340-352.
@article{ce496f6268d841658479bbf4cd55f6f2,
title = "Management and outcomes of giant prolactinoma: A series of 71 patients",
abstract = "Objective: To describe outcomes of patients with giant prolactinoma (≥4 cm) and identify predictors of therapeutic response. Methods: In this retrospective study, complete biochemical and structural response were defined as prolactin (PRL) ≤25 ng/mL and no visible tumor at follow-up, respectively. Results: Giant prolactinoma (median size, 4.8 cm [range, 4 to 9.8 cm]; median PRL, 5,927 ng/mL [range, 120 to 100,000 ng/mL]) was diagnosed in 71 patients. Treatments included: Dopamine agonists (DAs) (n = 70, 99{\%}), surgery (n = 30, 42{\%}), radiation (n = 10, 14{\%}), and somatostatin analogs (n = 2, 3{\%}). Patients treated with DA monotherapy were older compared with those who received subsequent therapies (47 years vs. 28 years; P = .003) but had similar initial PRL and tumor size. Surgically managed patients were younger compared with the nonsurgical group (35 years vs. 46 years; P = .02) and had lower initial PRL (3,121 ng/mL vs. 6,920 ng/mL; P = .02), yet they had similar tumor response. Hypopituitarism was more common following surgery compared to medical management: Adrenal insufficiency (69{\%} vs. 27{\%}; P<.001), hypothyroidism (67{\%} vs. 38{\%}; P = .02), growth hormone deficiency (24{\%} vs. 6{\%}; P = .04), and diabetes insipidus (17{\%} vs. 3{\%}; P = .04). Therapeutic response did not correlate with sex, age, initial PRL, tumor size, or first-line therapy mode. At median follow-up of 4.8 years, the median PRL was 18.3 ng/mL (range, 0.6 to 12,680 ng/mL), and final volume was 0.9 cm3 (range, 0 to 43.0 cm3). In those with available data, 36/65 (55{\%}) patients achieved PRL normalization, and 16/61 (26{\%}) had no visible tumor at follow-up. Conclusion: Most patients with giant prolactinoma have excellent response to DA. Sex, age, initial PRL, and tumor size do not predict therapeutic response.",
author = "Oksana Hamidi and {Van Gompel}, Jamie and Lucinda Gruber and Kittah, {Nana Esi} and Diane Donegan and Philbrick, {Kenneth A.} and Koeller, {Kelly K.} and Dana Erickson and Neena Natt and Nippoldt, {Todd B.} and Young, {William F.} and Irina Bancos",
year = "2019",
month = "4",
doi = "10.4158/EP-2018-0392",
language = "English (US)",
volume = "25",
pages = "340--352",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "4",

}

TY - JOUR

T1 - Management and outcomes of giant prolactinoma

T2 - A series of 71 patients

AU - Hamidi, Oksana

AU - Van Gompel, Jamie

AU - Gruber, Lucinda

AU - Kittah, Nana Esi

AU - Donegan, Diane

AU - Philbrick, Kenneth A.

AU - Koeller, Kelly K.

AU - Erickson, Dana

AU - Natt, Neena

AU - Nippoldt, Todd B.

AU - Young, William F.

AU - Bancos, Irina

PY - 2019/4

Y1 - 2019/4

N2 - Objective: To describe outcomes of patients with giant prolactinoma (≥4 cm) and identify predictors of therapeutic response. Methods: In this retrospective study, complete biochemical and structural response were defined as prolactin (PRL) ≤25 ng/mL and no visible tumor at follow-up, respectively. Results: Giant prolactinoma (median size, 4.8 cm [range, 4 to 9.8 cm]; median PRL, 5,927 ng/mL [range, 120 to 100,000 ng/mL]) was diagnosed in 71 patients. Treatments included: Dopamine agonists (DAs) (n = 70, 99%), surgery (n = 30, 42%), radiation (n = 10, 14%), and somatostatin analogs (n = 2, 3%). Patients treated with DA monotherapy were older compared with those who received subsequent therapies (47 years vs. 28 years; P = .003) but had similar initial PRL and tumor size. Surgically managed patients were younger compared with the nonsurgical group (35 years vs. 46 years; P = .02) and had lower initial PRL (3,121 ng/mL vs. 6,920 ng/mL; P = .02), yet they had similar tumor response. Hypopituitarism was more common following surgery compared to medical management: Adrenal insufficiency (69% vs. 27%; P<.001), hypothyroidism (67% vs. 38%; P = .02), growth hormone deficiency (24% vs. 6%; P = .04), and diabetes insipidus (17% vs. 3%; P = .04). Therapeutic response did not correlate with sex, age, initial PRL, tumor size, or first-line therapy mode. At median follow-up of 4.8 years, the median PRL was 18.3 ng/mL (range, 0.6 to 12,680 ng/mL), and final volume was 0.9 cm3 (range, 0 to 43.0 cm3). In those with available data, 36/65 (55%) patients achieved PRL normalization, and 16/61 (26%) had no visible tumor at follow-up. Conclusion: Most patients with giant prolactinoma have excellent response to DA. Sex, age, initial PRL, and tumor size do not predict therapeutic response.

AB - Objective: To describe outcomes of patients with giant prolactinoma (≥4 cm) and identify predictors of therapeutic response. Methods: In this retrospective study, complete biochemical and structural response were defined as prolactin (PRL) ≤25 ng/mL and no visible tumor at follow-up, respectively. Results: Giant prolactinoma (median size, 4.8 cm [range, 4 to 9.8 cm]; median PRL, 5,927 ng/mL [range, 120 to 100,000 ng/mL]) was diagnosed in 71 patients. Treatments included: Dopamine agonists (DAs) (n = 70, 99%), surgery (n = 30, 42%), radiation (n = 10, 14%), and somatostatin analogs (n = 2, 3%). Patients treated with DA monotherapy were older compared with those who received subsequent therapies (47 years vs. 28 years; P = .003) but had similar initial PRL and tumor size. Surgically managed patients were younger compared with the nonsurgical group (35 years vs. 46 years; P = .02) and had lower initial PRL (3,121 ng/mL vs. 6,920 ng/mL; P = .02), yet they had similar tumor response. Hypopituitarism was more common following surgery compared to medical management: Adrenal insufficiency (69% vs. 27%; P<.001), hypothyroidism (67% vs. 38%; P = .02), growth hormone deficiency (24% vs. 6%; P = .04), and diabetes insipidus (17% vs. 3%; P = .04). Therapeutic response did not correlate with sex, age, initial PRL, tumor size, or first-line therapy mode. At median follow-up of 4.8 years, the median PRL was 18.3 ng/mL (range, 0.6 to 12,680 ng/mL), and final volume was 0.9 cm3 (range, 0 to 43.0 cm3). In those with available data, 36/65 (55%) patients achieved PRL normalization, and 16/61 (26%) had no visible tumor at follow-up. Conclusion: Most patients with giant prolactinoma have excellent response to DA. Sex, age, initial PRL, and tumor size do not predict therapeutic response.

UR - http://www.scopus.com/inward/record.url?scp=85064766574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064766574&partnerID=8YFLogxK

U2 - 10.4158/EP-2018-0392

DO - 10.4158/EP-2018-0392

M3 - Article

C2 - 30995432

AN - SCOPUS:85064766574

VL - 25

SP - 340

EP - 352

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 4

ER -